Pharmaceuticals News and Research

RSS

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

Early lung infection exacerbates asthma risk in preterm birth children

A Swedish study of children admitted to hospital within the first year of life for lung infection has found that the increased risk this poses for later development of asthma is exacerbated by low gestational age.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.

9 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Seizures in people with epilepsy are commonly treated with anti-epileptic drugs (AEDs) but 30-40 percent do not achieve adequate seizure control, predisposing them to severe health risks, impaired quality of life and higher healthcare costs.

9 Dec 2013

Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain.

9 Dec 2013

New guide offers employers online and interactive toolkit to help support employees with cancer

A new guide developed by The National Business Group on Health and the National Comprehensive Cancer Network offers employers an online and interactive toolkit to help address the growing impact of cancer in the workplace.

6 Dec 2013

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. Sachdev Sidhu at the University of Toronto and the laboratory of Dr. Joseph Schlessinger of Yale University.

6 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

New project aims to reduce animal testing for drug development

Researchers at the University of East Anglia are launching a new project to develop methods which could one-day decrease the use of rats and mice in pharmaceutical testing.

6 Dec 2013

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.

6 Dec 2013

Scientists test affected human nerve cells to foretell efficacy of Alzheimer drugs

6 Dec 2013

Researchers update extensive toxicology database to track information about drugs toxic effects

Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and an important aspect of personalized medicine is to tailor therapies to individuals to reduce the chances of adverse events.

6 Dec 2013

Combination drug therapy does not work well in clinical trials for cancer patients, say researchers

Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

6 Dec 2013

Longer reads: HIV secrets, millennials' mental health and sleeping pills without side effects

Every week reporter Ankita Rao selects interesting reading from around the Web.

6 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Pharmaceuticals News and Research

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Early lung infection exacerbates asthma risk in preterm birth children

Adocia gets development and commercialization rights in nanotechnology for drug delivery

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

New guide offers employers online and interactive toolkit to help support employees with cancer

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

New project aims to reduce animal testing for drug development

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Scientists test affected human nerve cells to foretell efficacy of Alzheimer drugs

Researchers update extensive toxicology database to track information about drugs toxic effects

Combination drug therapy does not work well in clinical trials for cancer patients, say researchers

Longer reads: HIV secrets, millennials' mental health and sleeping pills without side effects

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence